Abstract
Yufeng Gong, Ziqin Xiong, Chutian Wu, Congyan Tan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cystatin C-guided dosing nomogram improves target attainment for cefepime in the critically ill
10.1097/ccm.0000000000006622 · 2025
Prediction of lacosamide concentrations to support dose optimization during pregnancy
10.1111/epi.18184 · 2025
Usage of rabbit anti-thymocyte/anti-T-lymphocyte globulins (ATG/ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: best practice recommendations from the EBMT practice harmonisation and guidelines committee
10.1038/s41409-025-02742-8 · 2025
Machine learning application in a phase I clinical trial allows for the identification of clinical-biomolecular markers significantly associated with toxicity
10.1002/cpt.2511 · 2022
First dose target attainment with extended infusion regimens of piperacillin and meropenem
10.1186/s13054-025-05445-0 · 2025
Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients
10.1097/ftd.0000000000001217 · 2024
Drug exposure of long-acting cabotegravir and rilpivirine in older people with human immunodeficiency virus: a pharmacokinetic modeling study
10.1093/ofid/ofae171 · 2024
Cefepime population pharmacokinetics, antibacterial target attainment, and estimated probability of neurotoxicity in critically ill patients
10.1128/aac.00309-23 · 2023
Population pharmacokinetics of meropenem across the adult lifespan
10.1007/s40262-024-01465-1 · 2025
Population pharmacokinetic model development of tacrolimus in pediatric and young adult patients undergoing hematopoietic cell transplantation
10.3389/fphar.2021.750672 · 2021
Impact of obesity on brexpiprazole pharmacokinetics: proposal for improved initiation of treatment
10.1002/jcph.1947 · 2022
Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy
10.1016/j.cmi.2022.03.031 · 2022
How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
10.1128/aac.01729-23 · 2024
Steady-state drug exposure of repeated IV bolus administration for a one compartment pharmacokinetic model with sigmoidal hill elimination
10.1007/s11538-024-01375-0 · 2024
Physiologically based pharmacokinetic modeling of vancomycin and its comparison with population pharmacokinetic model in neonates
10.1002/jcph.6126 · 2025
Pharmacokinetic model selection for personalized infliximab dosing in IBD
10.1002/psp4.70152 · 2025
Nonlinear mixed-effect pharmacokinetic modeling and distribution of doxycycline in healthy female donkeys after multiple intragastric dosing–preliminary investigation
10.3390/ani11072047 · 2021
Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients
10.1093/jac/dkaf329 · 2025
Population pharmacokinetic analysis of atomoxetine and its metabolites in children and adolescents with attention-deficit/hyperactivity disorder
10.1002/cpt.3155 · 2024
Pharmacokinetic evaluation of aripiprazole monohydrate as a once every 2-months long-acting injectable antipsychotic for schizophrenia
10.1080/17425255.2025.2545918 · 2025
Data-driven identification of factors that influence the quality of adverse event reports: 15-year interpretable machine learning and time-series analyses of VigiBase and QUEST
10.2196/49643 · 2024
A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors
10.1111/cts.12963 · 2021
Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight
10.1016/j.ijantimicag.2023.106751 · 2023
The effect of polymorphisms and other biomarkers on infliximab exposure in paediatric inflammatory bowel disease: development of a population pharmacokinetic model
10.1007/s40272-024-00621-1 · 2024
Designing drug regimens that mitigate nonadherence
10.1007/s11538-021-00976-3 · 2022
Exposure–response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome
10.1007/s12325-024-02796-y · 2024
Reinforcement learning and PK-PD models integration to personalize the adaptive dosing protocol of erdafitinib in patients with metastatic urothelial carcinoma
10.1002/cpt.3176 · 2024
Precision dosing in presence of multiobjective therapies by integrating reinforcement learning and PK–PD models: application to givinostat treatment of polycythemia vera
10.1002/psp4.70012 · 2025
Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: Proof-of-concept
10.3389/fped.2023.1288376 · 2023
Adaptive cancer therapy in the age of generative artificial intelligence
10.1177/10732748241264704 · 2024
Multiple model optimal sampling promotes accurate vancomycin area-under-the-curve estimation using a single sample in critically ill children
10.1097/ftd.0000000000001293 · 2025
Bayesian forecasting for intravenous tobramycin dosing in adults with cystic fibrosis using one versus two serum concentrations in a dosing interval
10.1097/ftd.0000000000000900 · 2021
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
10.1093/jac/dkae318 · 2024
Ganciclovir pharmacokinetics and individualized dosing based on covariate in lung transplant recipients
10.3390/pharmaceutics14020408 · 2022
Reinforcement learning derived chemotherapeutic schedules for robust patient-specific therapy
10.1038/s41598-021-97028-6 · 2021
Consideration of height-based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations
10.1111/bcp.15154 · 2022
A digital twin of glimepiride for personalized and stratified diabetes treatment
10.3389/fphar.2025.1686415 · 2025
A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole
10.1080/03007995.2025.2456014 · 2025
Deep reinforcement learning for closed-loop blood glucose control
10.48550/arxiv.2009.09051 · 2020
Artificial intelligence-based model for dose prediction of sertraline in adolescents: a real-world study
10.1080/17512433.2024.2304009 · 2024
Population pharmacokinetics of subcutaneous alemtuzumab in kidney transplantation
10.1111/bcp.15608 · doi-reference
Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants
10.1016/j.ejps.2025.107301 · doi-reference
Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the in vivo prediction of individual hepatic clearance
10.21037/jgo-2024-963 · doi-reference
Characterizing pharmacokinetic variability of topiroxostat in Chinese population: insights from a phase I randomized clinical trial
10.2174/0113892002348045241210071452 · doi-reference
Physiologically based pharmacokinetic modeling of ritonavir-oxycodone drug interactions and its implication for dosing strategy
10.1016/j.ejps.2024.106697 · doi-reference
A safe-enhanced fully closed-loop artificial pancreas controller based on deep reinforcement learning
10.1371/journal.pone.0317662 · doi-reference
Population pharmacokinetics of vancomycin in non-extremely preterm neonates based on real-world studies: influence of daily fluid input and diuretics
10.1128/spectrum.02274-24 · doi-reference
Individualized dosing parameters for tacrolimus in the presence of voriconazole: a real-world PopPK study
10.3389/fphar.2024.1439232 · doi-reference
Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (humira®) in healthy subjects and ankylosing spondylitis patients: population pharmacokinetic modeling
10.17219/acem/145947 · doi-reference
Deep reinforcement learning for automated insulin delivery systems: algorithms, applications, and prospects
10.3390/ai6050087 · doi-reference
Optimal STI controls for HIV patients based on an efficient deep Q learning method
10.1016/j.jtbi.2024.111914 · doi-reference
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling
10.1002/bdd.2325 · doi-reference
Managing delayed or missed pregabalin doses in patients with focal epilepsy: a monte carlo simulation study
10.1007/s11096-023-01657-y · doi-reference
Tacrolimus exposure prediction using machine learning
10.1002/cpt.2123 · doi-reference
Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis
10.1093/bjd/ljae439 · doi-reference
Prediction of prolonged opioid use after surgery in adolescents: insights from machine learning
10.1213/ane.0000000000005527 · doi-reference
Pharmacokinetics of ampicillin-sulbactam in azotemic and non-azotemic dogs
10.1111/jvp.13506 · doi-reference
Exposure–response analysis for aripiprazole once-monthly in patients diagnosed with bipolar I disorder
10.1002/cpdd.1580 · doi-reference
Population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar I disorder
10.1002/cpdd.1397 · doi-reference
Integrating real-world data and machine learning: a framework to assess covariate importance in real-world use of alternative intravenous dosing regimens for atezolizumab
10.1111/cts.70077 · doi-reference
Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice
10.1128/aac.01118-24 · doi-reference
Getting the dose right using physiologically-based pharmacokinetic modeling: dexamethasone to prevent post-extubation stridor in children as proof of concept
10.3389/fped.2024.1416440 · doi-reference
Pharmacokinetic model-informed precision dosing of natalizumab in multiple sclerosis
10.1002/psp4.70014 · doi-reference
Model-informed clinical development of 6-monthly injection of paliperidone palmitate in patients with schizophrenia: dosing strategies guided by population pharmacokinetic modeling and simulation (part II)
10.1007/s13318-024-00899-z · doi-reference
Model-informed clinical development of once-every-6-month injection of paliperidone palmitate in patients with schizophrenia: a pharmacometric bridging approach (part I)
10.1007/s13318-024-00900-9 · doi-reference
Optimizing mycophenolate therapy in renal transplant patients using machine learning and population pharmacokinetic modeling
10.3390/medsci13040235 · doi-reference
Model-informed reinforcement learning for enabling precision dosing Via adaptive dosing
10.1002/cpt.3356 · doi-reference
Personalized cancer chemotherapy schedule: a numerical comparison of performance and robustness in model-based and model-free scheduling methodologies
10.48550/arxiv.1904.01200 · doi-reference
Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease
10.1007/s10928-023-09874-8 · doi-reference
Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia a: a population pharmacokinetic model
10.3324/haematol.2019.241554 · doi-reference
Personalizing biologic therapy in psoriasis: development, validation, and user testing of a precision-dosing dashboard
10.1016/j.jid.2025.01.031 · doi-reference
Model informed dosing of hydroxycholoroquine in COVID‐19 patients: learnings from the recent experience, remaining uncertainties and gaps
10.1111/bcp.14436 · doi-reference
Population pharmacokinetic modeling of total and free ceftriaxone in critically ill children and young adults and monte carlo simulations support twice daily dosing for target attainment
10.1128/aac.01427-21 · doi-reference
Machine learning approach in dosage individualization of isoniazid for tuberculosis
10.1007/s40262-024-01400-4 · doi-reference
Use of machine learning for dosage individualization of vancomycin in neonates
10.1007/s40262-023-01265-z · doi-reference
Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: a prospective observational study
10.1111/bcp.14578 · doi-reference
Optimizing phenobarbital dosing in critically ill patients with refractory and superrefractory status epilepticus using a population pharmacokinetic model
10.1111/epi.18517 · doi-reference
Population pharmacokinetics and dose optimization of vancomycin in critically ill children
10.1007/s13318-021-00695-z · doi-reference
Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations
10.1080/17512433.2025.2594496 · doi-reference
Oral ibuprofen is more effective than intravenous ibuprofen for closure of a patent ductus arteriosus: can pharmacokinetic modeling help us to understand why?
10.1159/000526210 · doi-reference